A green background with a white border. White text at the top says: 2025 Annual Report Below text says: The board voted to approve the 2025 Annual Report for the Oregon Legislature. The report outlines the board's activities, price trend analyses, and policy recommendations to improve drug affordability across Oregon. To the right is a screenshot of the yellow report cover with a photo of a family.

A green background with a white border. White text at the top says: 2025 Affordability Reviews. Below text says: Board members identified several top priority drugs that present significant affordability challenges for Oregonians: Cosentyx Creon Vraylar Trulicity Lantus SoloStar Their final vote will be at their January 21 meeting. Icons of an injection, pills, and a price tag with three dollar signs.

A green background with a white border. White text at the top says: Next Year. Below text says: The board is already preparing for 2026 affordability reviews, developing a preliminary list of 137 drug products for review based on 2024 data. To ensure patient voices are heard, a major outreach project will launch in spring of 2026 with community meetings in Salem, Redmond, Portland, and Beaverton, and online. An icon of the state of Oregon with hands raised inside. A speech bubble coming from the state with a pill bottle and a price tag with three dollar signs.

A green background with a white border. White text at the top says: Looking Ahead. White text below says: Next PDAB Meeting: January 21, 2026 at 8 am, Register for Zoom Link. Board members will vote on the final list of unaffordable drugs from their 2025 affordability reviews. A white icon of a calendar with the date January 21.

This Wednesday the #Oregon #PDAB met. Here are the highlights:
- Annual Report
- 2025 #Affordability Reviews
- Next Year's Plan

Next meeting: Jan 21, 2026 at 8 am. Zoom link at dfr.oregon.gov/pdab

#Cosentyx #Creon #Vraylar #Trulicity #LantusSoloStar #HealthPolicy

Cosentyx (Secucinumab) | Relatório de avaliação de financiamento público disponível na Infomed | Deferimento Infarmed

Cosentyx (Secucinumab) | Relatório de avaliação de financiamento público disponível na Infomed | Deferimento

Saiba mais em: 🔗 swki.me/q93oyrw3
#infarmed #medicamentos #financiamentopúblico #cosentyx

Have you or someone you know paid a high price for: Cosentyx Generic: Secukinumab Therapy Class: Dermatological Consider sharing your story with the Oregon Prescription Drug Affordability Board

Have you or someone you know paid a high price for #Cosentyx?

The #Oregon #PDAB is reviewing high-cost drugs that strain Oregon patients & they need to hear from YOU! Next meeting: Aug. 20 at 8 am. Comment at: bit.ly/or-pdab-comment

#Psoriasis #AnkylosingSpondylitis #PsoriaticArthritis #OCAP

The Oregon Prescription Drug Affordability Board (PDAB) is reviewing high-cost drugs that may strain Oregon patients or our health care system. They want to hear your experience with high costs on ANY of the prescription drugs on their review list. Use the website below to share: bit.ly/or-pdab-comment

On August 20, the Oregon PDAB will review: Trelegy* (Fluticasone furoate; Umeclidinum bromide; Vilanterol trifenatate) Eliquis* (Apixaban) Xarelto (Rivaroxaban) Cosentyx (Secukinumab) Creon (Pancrelipase [Amylase; Lipase; Protease]) * = No generic currently avaiable

PDAB Has Already Reviewed: Vraylar* (Cariprazine HCl ) Entresto (Sacubitril; Valsartan) Ajovy (Fremanezumab-vfrm) Emgality (Galcanezumab-gnlm) Nurtec (Rimegepant/ rimegepant sulfate) Ubrelvy* (Ubrogepant) *=no generic currently available you can still share your story about these drugs until November 19

The #Oregon #PDAB is meeting to review: #Trelegy, #Eliquis, #Xarelto, #Cosentyx, & #Creon on Aug. 20 at 8 am!

If you or someone you know has taken any of these (or any others on their list), they need to hear from you! Send a letter/sign up to speak at bit.ly/or-pdab-comment

Novartis drug flunks phase 3 test in giant cell arteritis Novartis hopes of bringing Cosentyx to patients with giant cell arteritis seem to be over after the drug missed all the endpoints in a phase 3 trial.

#Novartis' blockbuster immunology drug #Cosentyx has disappointed in a phase 3 trial involving patients with #giantcellarteritis, a debilitating #autoimmunedisease affecting the arteries.

pharmaphorum.com/news/novarti...

Novartis Cosentyx fails in late-stage giant cell arteritis trial Investing.com -- Novartis (SIX:NOVN) announced Thursday that its Cosentyx drug did not meet its primary goal in a Phase III trial for adults with giant cell arteritis (GCA). The drug failed to demonstrate an improvement in sustained remission among patients with newly diagnosed or relapsing GCA, according to the Swiss pharmaceutical company. Shreeram Aradhye, president of development and chief medical officer at Novartis, said: "While the Phase III results did not replicate the positive outcomes observed in the Phase II trial, we remain committed to continuing to drive scientific progress and deepening the understanding of immune-mediated diseases." This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Novartis #Cosentyx #GiantCellArteritis #ClinicalTrials #PharmaceuticalNews

Novartis Updates on Phase III Results of Cosentyx for Giant Cell Arteritis Novartis announced results from the Phase III GCAptAIN trial for Cosentyx in giant cell arteritis, noting it missed its primary endpoint but showed safety consistency.

Novartis Updates on Phase III Results of Cosentyx for Giant Cell Arteritis #United_States #Novartis #East_Hanover,_NJ #Cosentyx #GCAptAIN